Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88,808 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
Zheng L, Xiong A, Wang S, Xu J, Shen Y, Zhong R, Lu J, Chu T, Zhang W, Li Y, Zheng X, Han B, Zhong H, Nie W, Zhang X. Zheng L, et al. Among authors: zhang w, zhang x. Front Immunol. 2023 Jan 26;14:1094378. doi: 10.3389/fimmu.2023.1094378. eCollection 2023. Front Immunol. 2023. PMID: 36776882 Free PMC article.
Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study.
Pan Y, Zhu X, Liu J, Zhong J, Zhang W, Shen S, Jin R, Liu H, Ye F, Hu K, Xu D, Zhang Y, Chen Z, Xing B, Zhou L, Chen Y, Zeng Y, Liang X, Kuang M, Song T, Xiang B, Wang K, Sun H, Xu L; China Liver Cancer Study Group Young Investigators (CLEAP). Pan Y, et al. Among authors: zhang w, zhang y. Front Immunol. 2023 Apr 26;14:1138355. doi: 10.3389/fimmu.2023.1138355. eCollection 2023. Front Immunol. 2023. PMID: 37180173 Free PMC article.
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial.
Tian W, Ren Y, Lu J, Jing C, Zhang W, Li H, Wang T, Hou Z, Yang T, Zhu W, Zhang Y, Shan B, Yang H, Cheng X, Wang H. Tian W, et al. Among authors: zhang w, zhang y. BMC Med. 2024 Aug 26;22(1):344. doi: 10.1186/s12916-024-03564-z. BMC Med. 2024. PMID: 39183277 Free PMC article. Clinical Trial.
Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive-stage small-cell lung cancer patients (DURABLE study).
Zhang B, Zhong H, Shi C, Gao Z, Zhong R, Gu A, Wang W, Chu T, Xiong L, Zhang W, Wang H, Zhang X, Han B. Zhang B, et al. Among authors: zhang w, zhang x. Clin Respir J. 2023 Dec;17(12):1361-1367. doi: 10.1111/crj.13715. Epub 2023 Nov 10. Clin Respir J. 2023. PMID: 37947242 Free PMC article. Clinical Trial.
88,808 results
You have reached the last available page of results. Please see the User Guide for more information.